Home

For your appropriate adult patients living with schizophrenia or maintenance monotherapy treatment of bipolar I disorder

Extend support to two months with dual-indicated ABILIFY ASIMTUFII® (aripiprazole)

 

ABILIFY ASIMTUFII provides the stability*† you know from ABILIFY MAINTENA® (aripiprazole) for adult patients who are stable on an oral antipsychotic or on ABILIFY MAINTENA

The clinical profile of ABILIFY ASIMTUFII is based on the adequate and well-controlled studies of ABILIFY MAINTENA
in the treatment of schizophrenia and maintenance monotherapy treatment of bipolar I disorder in adults.

Establish tolerability with oral aripiprazole before initiating therapy. For patients already stable on oral aripiprazole or another oral antipsychotic, after the first injection, continue treatment with the antipsychotic for 14 consecutive days. For more information, see Dosing & Administration in prescribing information.

Image
bridge
Image
bridge

Explore our portfolio history

 

Learn more about the two decades of treatment provided by our portfolio of products.

*In a 52-week randomized study (N=403; P<0.0001), ABILIFY MAINTENA has been proven to delay time to relapse in adults living with schizophrenia.1

In a 52-week multiphase study (N=266; P<0.0001), ABILIFY MAINTENA has been proven as a maintenance treatment to delay time to recurrence of any mood disorder in adults living with bipolar I disorder.2

In a 32-week, open-label study (N=266), ABILIFY ASIMTUFII provided comparable concentrations, and thus comparable efficacy, to ABILIFY MAINTENA.3